Skip to main content
. 2017 Sep 14;8(59):99580–99586. doi: 10.18632/oncotarget.20884

Figure 3. ICAM-1 expression in patient paired samples of disease progression.

Figure 3

(A) ICAM-1 membrane expression was analyzed in our in-house TMA comprised of paired primary tumors, lymph node (LN) metastases and distant metastases. Intensity staining of ICAM-1 was scored as none, low, intermediate or high. (B) Representative staining patterns (×4) of ICAM-1 in melanocytic specimens.